3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Dermatologic
2
Conditions
Mycosis Fungoides
3
Lymphoma, T-Cell, Cutaneous
3
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, T-Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Lymphatic Diseases
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large B-Cell, Diffuse
1
Leukemia-Lymphoma, Adult T-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Interventions
10-propargyl-10-deazaaminopterin
6
Brentuximab Vedotin
5
romidepsin
3
Vitamin B 12
3
Rituximab
3
Folic Acid
3
Cyclophosphamide
3
tenalisib
2
cobomarsen
2
belinostat
2
Vincristine
2
Prednisone
2
Gemcitabine
2
Doxorubicin
2
zanubrutinib
1
zanolimumab
1
venetoclax
1
tislelizumab
1
quisinostat
1
pembrolizumab
1
mogamulizumab
1
fostamatinib
1
forodesine
1
fludarabine
1
enzastaurin
1
enzalutamide
1
duvelisib
1
denileukin diftitox
1
darinaparsin
1
cc-486
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, T-Cell
×
cobomarsen
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts
NCT03837457
2020-11-19
PRISM
miRagen Therapeutics, Inc.
Phase 2
Terminated
8 enrolled